Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868624 | 0.84 | TSHR (0.34) | TSHRLMNAROCK2HPGDUSP2 | |
| SCHEMBL14868670 | 0.82 | TSHR (0.33) | TSHRLMNAROCK2HPGDUSP2 | |
| SCHEMBL24433739 | 0.76 | LMNA (0.32) | LMNA | |
| SCHEMBL18624786 | 0.73 | LMNA (0.46) | LMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL14868654 | 0.73 | GRM5 (0.39) | LMNAHPGD | |
| SCHEMBL24433703 | 0.72 | L3MBTL1 (0.32) | — | |
| SCHEMBL17790231 | 0.72 | — | — | |
| SCHEMBL14868321 | 0.71 | ALOX12 (0.47) | LMNAHPGDALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2246639 | 0.70 | MAPT (0.48) | LMNAHPGDALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL17186315 | 0.70 | MAPT (0.48) | LMNAHPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | TSHR 2290/4885LMNA 2222/4885ROCK2 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.